The global cell therapy technologies market is projected to reach USD 8.0 billion by 2027 from USD 4.0 billion in 2022, at a CAGR of 14.6% during the forecast period. Market growth is driven mainly by increasing research in regenerative medicine along with stem cell research, cancer research, and cell biology research. Moreover, cell therapy technologies are extensively used in research centers and research institutes for life science and biopharmaceutical R&D. Such factors are fueling the market growth.
The Stem Cell Therapy Market report tracks the latest trends in the industry and studies their impact on the overall market. It also assesses the market dynamics, covering the key demand and price indicators, along with analysing the market based on the SWOT and Porter’s Five Forces models.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=213334978
Global Cell Culture Market Vendor Analysis
The global cell therapy technologies market is consolidated. The prominent players operating in this market include Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Lonza Group (Switzerland), Sartorius AG (Germany), Terumo BCT (US), Becton, Dickinson and Company (US), Fresenius SE & Co. KGaA (Germany), Avantor, Inc. (US), Bio-Techne Corporation (US), Corning Incorporated (US), FUJIFILM Irvine Scientific (US), MaxCyte Inc. (US), Werum IT Solutions GmbH (Germany), RoosterBio Inc. (US), SIRION Biotech GmbH (Germany), TrakCel (UK), L7 Informatics, Inc. (US), Miltenyi Biotec GmbH (Germany), STEMCELL Technologies (Canada), GPI Iberia (Spain), MAK-SYSTEM (US), OrganaBio, LLC (US), IxCells Biotechnology (China), and Wilson Wolf Manufacturing Corporation (US). Product launches and acquisitions are the key growth strategies undertaken by these companies to maintain their positions in the market.
Thermo Fisher Scientific
Thermo Fisher Scientific offers a complete and integrated portfolio of solutions and services for clinical science, laboratory research, and analysis. It operates in four business segments—Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. Its Life Sciences Solutions segment offers a wide range of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as the diagnosis of diseases.
Merck KGaA
Merck operates through three business segments, namely, Healthcare, Life Science, and Performance Materials. The Life Science segment offers life science products and services for research and diagnostic purposes. Merck offers products in the cell therapy technologies market through its Life Science segment.
Danaher Corporation
Danaher Corporation operates through three strategic segments—Environmental and Applied Solutions, Life Sciences, and Diagnostics. The Diagnostics segment offers a wide range of products through its key brands—SCIEX, Beckman Coulter, Leica Biosystems, Leica Microsystems, Radiometer, and Cepheid. Beckman Coulter and Cytiva, subsidiaries of Danaher Corporation, cater to the cell therapy technologies market. Beckman develops, manufactures, and markets products in automation, diagnostics, and chemistry. Cytiva, which was formerly a part of GE Healthcare Life Sciences, offers cell therapy development solutions, such as cell processing, cell banking, and point-of-care technologies.
Request for Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=213334978
